Eur J Cancer: Letrozole + Palbociclib Neoadjuvant Therapy May Replace Chemotherapy for High-Risk ER+HER2- Breast Cancer

In addition to being an additional adjuvant therapy, CDK4/6 inhibitor combination with endocrine therapy may also be a less toxic alternative to chemotherapy in postmenopausal women with high-risk estrogen receptor-positive, HER2-negative breast cancer
.

The phase 2 NEOPAL trial is a multicenter, international, randomized clinical study.
The primary endpoint analysis showed that the clinical and pathological response of the above patients treated with the letrozole-palbociclib combination regimen was significantly different from that of anthracycline-violet.
Cedar drugs are comparable to sequential chemotherapy
.

This article reports the secondary endpoints of the NEOPAL trial, including progression-free survival (PFS) and invasive disease-free survival (iDFS)
.

Progression-free survival (a), invasive disease-free survival (b), breast cancer-specific survival (c), and overall survival (d) in the two groups of patients

In this trial, a total of 106 patients were randomly assigned to two groups (53 each) to receive either letrozole-palbociclib (experimental group) or chemotherapy (control group)
.

In conclusion, the NEOPAL study shows that the letrozole-palbociclib neoadjuvant therapy regimen is expected to save some patients with intraluminal breast cancer from the pain of chemotherapy, and at the same time obtain a better long-term prognosis
.

Original source:

Delaloge Suzette, Dureau Sylvain, D'Hondt Véronique et al.